Bryan Garnier - CERES POWER (CWR.L) CERES POWER HOLDINGS - Conviction BUY Top Picks | GBP2000 VS. GBP1600 (+81%)

Report

Bryan Garnier

Xavier Regnard

CERES POWER HOLDINGS - Conviction BUY Top Picks | GBP2000 VS. GBP1600 (+81%)

CERES POWER HOLDINGS - Conviction BUY Top Picks | GBP2000 VS. GBP1600 (+81%)
Ceres adds a string to its bow with electrolysers

GBP180m fundraising supported by Bosch and Weichai
Expanding into electrolysers (SOEC), a massive opportunity
Positive stance confirmed, Conviction Buy, TP 2000p vs 1600p

18/03/2021 1 EN

Underlying

CERES POWER

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Xavier Regnard

Other Reports on these Companies

Pelham Smithers Associates Ltd

PSA Autos: Fuel Cell Electric Trucks – A Silent Evolution

Whereas hydrogen fuel cell systems have not had a break-through in the passenger car market, the situation for the commercial vehicle market looks very different: For heavy-duty trucks in particular, FCVs are superior to BEVs when it comes to charging times, payload and driving range. In this report, analyst Julie Boote assesses the outlook for hydrogen fuel cell trucks and explains how the main global participants are positioned.

March 30, 2023 March 30, 2023 1 EN

Hybridan

Hybridan Small Cap Feast - 16 Mar 23

16 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyo...

March 16, 2023 March 16, 2023 1 EN

Bryan Garnier

Energy transition & Sustainability Green hydrogen finally ready for take-off | HydrogenPro initiation of coverage Buy – Tprice NOK50/share

The green hydrogen market is moving from a proof-of-concept stage to commercial implementation, accompanied by strong growth in equipment sales. According to BloombergNEF (BNEF), electrolyser sales are projected to at least quadruple in 2022, from c.460 MW in 2021 to 1.8-2.5 GW in 2022, depending on the scenario HydrogenPro initiation of coverage Buy – Tprice NOK50/share Ceres Power Still one of our favourite stocks in the sector ITM Power Struggling to deliver on time McPhy Heading for new cuts in consensus estimates NEL Well positioned in the US market

September 30, 2022 September 30, 2022 1 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

April 25, 2025 April 25, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

April 25, 2025 April 25, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

April 25, 2025 April 25, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CERES POWER HOLDINGS - Conviction BUY Top Picks | GBP2000 VS. GBP1600 (+81%)

PSA Autos: Fuel Cell Electric Trucks – A Silent Evolution

Hybridan Small Cap Feast - 16 Mar 23

Energy transition & Sustainability Green hydrogen finally ready for take-off | HydrogenPro initiation of coverage Buy – Tprice NOK50/share

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe